Apollomics Statistics
Total Valuation
Apollomics has a market cap or net worth of $7.74 million. The enterprise value is -$13.47 million.
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, after market close.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Apollomics has 1.10 million shares outstanding. The number of shares has decreased by -77.42% in one year.
| Current Share Class | 1.10M |
| Shares Outstanding | 1.10M |
| Shares Change (YoY) | -77.42% |
| Shares Change (QoQ) | +4.36% |
| Owned by Insiders (%) | 24.49% |
| Owned by Institutions (%) | 1.17% |
| Float | 657,383 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.07 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.23.
| Current Ratio | 2.25 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -237.40 |
Financial Efficiency
Return on equity (ROE) is -149.31% and return on invested capital (ROIC) is -79.94%.
| Return on Equity (ROE) | -149.31% |
| Return on Assets (ROA) | -62.74% |
| Return on Invested Capital (ROIC) | -79.94% |
| Return on Capital Employed (ROCE) | -242.56% |
| Revenue Per Employee | $46,689 |
| Profits Per Employee | -$1.27M |
| Employee Count | 45 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.22% in the last 52 weeks. The beta is 0.98, so Apollomics's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -89.22% |
| 50-Day Moving Average | 8.93 |
| 200-Day Moving Average | 15.59 |
| Relative Strength Index (RSI) | 37.88 |
| Average Volume (20 Days) | 7,378 |
Short Selling Information
The latest short interest is 3,707, so 0.34% of the outstanding shares have been sold short.
| Short Interest | 3,707 |
| Short Previous Month | 5,212 |
| Short % of Shares Out | 0.34% |
| Short % of Float | 0.56% |
| Short Ratio (days to cover) | 0.17 |
Income Statement
In the last 12 months, Apollomics had revenue of $2.10 million and -$57.11 million in losses. Loss per share was -$62.95.
| Revenue | 2.10M |
| Gross Profit | 2.10M |
| Operating Income | -53.18M |
| Pretax Income | -172.59M |
| Net Income | -57.11M |
| EBITDA | -53.10M |
| EBIT | -53.18M |
| Loss Per Share | -$62.95 |
Full Income StatementBalance Sheet
The company has $25.93 million in cash and $4.72 million in debt, giving a net cash position of $21.21 million or $19.23 per share.
| Cash & Cash Equivalents | 25.93M |
| Total Debt | 4.72M |
| Net Cash | 21.21M |
| Net Cash Per Share | $19.23 |
| Equity (Book Value) | 20.81M |
| Book Value Per Share | 18.92 |
| Working Capital | 15.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.80 million and capital expenditures -$24,000, giving a free cash flow of -$34.82 million.
| Operating Cash Flow | -34.80M |
| Capital Expenditures | -24,000 |
| Free Cash Flow | -34.82M |
| FCF Per Share | -$31.58 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,531.08% |
| Pretax Margin | -2,718.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Apollomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 77.42% |
| Shareholder Yield | 77.42% |
| Earnings Yield | -737.83% |
| FCF Yield | -449.88% |
Analyst Forecast
The average price target for Apollomics is $425.00, which is 5,954.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $425.00 |
| Price Target Difference | 5,954.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on November 25, 2024. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Nov 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
Apollomics has an Altman Z-Score of -25.02 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -25.02 |
| Piotroski F-Score | 2 |